RecruitingNCT06674772

Molecular Phenotyping of Migraine Patients According to Sex and Age Through CGRP Quantification

Fenotipado Molecular De Pacientes Con Migraña Según Edad Y Sexo a Través De La Cuantificación De CGRP En Saliva Para Realizar Medicina De Precisión: Estudio FAST


Sponsor

Hospital Universitari Vall d'Hebron Research Institute

Enrollment

440 participants

Start Date

Nov 29, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

Patients will be asked to visit the study center 2 times, the first time for clinical assessment and a second time for sample collection. Healthy controls will only be asked to visit the study center for sample collection. A sample of blood and saliva will be collected in order to measure CGRP levels and DNA and hormone testing.


Eligibility

Min Age: 6 YearsMax Age: 75 Years

Inclusion Criteria2

  • Migraine patients according to ICHD-3 criteria
  • Healthy controls paired to patient age and sex, without headache and without first degree family history of headache.

Exclusion Criteria5

  • Presence of any major medical or neurological illness.
  • Presence of any salivary gland malfunction.
  • Abuse or dependence to tobacco, alcohol or any drug in the previous 12 months before the enrollment.
  • Active migraine preventive treatment.
  • Pregnant or breastfeeding female.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTSaliva test

Sampling of CGRP in saliva and DNA blood test and sex hormones blood test.


Locations(1)

Vall d'Hebron University Hospital

Barcelona, Barcelona, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06674772


Related Trials